Development of an adjuvant therapy for severe malaria with the hemoglobin vesicle, an artificial oxygen carrier.

我们利用啮齿动物疟疾模型研究了HbV作为严重疟疾辅助治疗的潜力。Balb/c小鼠接种伯氏疟原虫。接种后6 d开始尾静脉HbV或生理盐水感染。每日给药至死亡，HbV组和生理盐水组小鼠的寄生率和体重均无显著差异。然而，我们观察到，在给药后，HbV治疗的小鼠比生理盐水治疗的小鼠变得更加活跃。为了评价HbV治疗的效果，进行了旋转棒性能试验。两组小鼠在旋转棒上的骑行时间比较显示，HbV治疗小鼠的骑行时间明显延长。HbV输注可能改善了小鼠的贫血并减轻了严重疟疾的并发症。HbV作为人类辅助治疗以及在流行地区挽救患者生命的潜力巨大。

We investigated the potential of HbV as an adjuvant therapy for severe malaria using rodent malaria models. Balb/c mice were inoculated with Plasmodium berghei. The HbV or saline infection was started in tail vein from 6-day after inoculation. No significant difference in parasitemia and body weight of the mice was observed between the HbV and saline treated groups after daily treatment until they died. However, we observed that, immediately after its administration, the HbV treated mice became more active comparing the saline treated mice. To evaluate the effects of the HbV treatment, the rotarod performance test was carried out. The riding time on the rotarod compared between the 2 groups revealed significant extension of the time in mice treated with the HbV. The HbV transfusion may have improved the anemia and mitigated the complication of severe malaria in mice. The HbV has high potential as adjuvant therapy for human as well to save the lives of patients in the endemic areas.